Equities researchers at HC Wainwright assumed coverage on shares of Lipocine Inc. (NASDAQ:LPCN) in a research report issued on Monday. The brokerage set a “buy” rating and a $25.00 price target on the specialty pharmaceutical company’s stock.

The analysts wrote, “H.C. Wainwright Thinks Lipocine’s Stock is Going to Recover | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h */

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/lipocine-inc-lpcn-coverage-initiated-at-hc-wainwright.html

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘http://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=b00703a8b3&wpp_id=456467’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
/* Send request */
xhr.send( params );


(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;


Stock Market
Best Performing Analysts

Basic Materials
Consumer Goods
Industrial Goods

Most Popular
Contact Us

Home » H.C. Wainwright Thinks Lipocine’s Stock is Going to Recover”

Separately, Canaccord Genuity reissued a “buy” rating and set a $6.00 target price (down from $15.00) on shares of Lipocine in a research report on Saturday, July 2nd.

Shares of Lipocine (NASDAQ:LPCN) traded down 3.95% during mid-day trading on Monday, reaching $3.65. The company’s stock had a trading volume of 997,226 shares. The company has a 50 day moving average price of $3.94 and a 200 day moving average price of $6.34. Lipocine has a 12 month low of $2.51 and a 12 month high of $14.80. The stock’s market capitalization is $66.64 million.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. On average, equities research analysts anticipate that Lipocine will post ($1.31) earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Landscape Capital Management L.L.C. acquired a new position in Lipocine during the first quarter valued at approximately $385,000. Royce & Associates LP increased its stake in shares of Lipocine by 2.3% in the first quarter. Royce & Associates LP now owns 839,357 shares of the specialty pharmaceutical company’s stock valued at $8,519,000 after buying an additional 19,134 shares in the last quarter. California State Teachers Retirement System acquired a new stake in shares of Lipocine during the second quarter valued at about $106,000. Dimensional Fund Advisors LP increased its stake in shares of Lipocine by 1.5% in the second quarter. Dimensional Fund Advisors LP now owns 296,302 shares of the specialty pharmaceutical company’s stock valued at $901,000 after buying an additional 4,464 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Lipocine by 14.1% in the second quarter. Vanguard Group Inc. now owns 536,582 shares of the specialty pharmaceutical company’s stock valued at $1,631,000 after buying an additional 66,199 shares in the last quarter. 47.22% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

5 Day Chart for NASDAQ:LPCN

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.